🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to scientists.

An International Health Concern

The sexually transmitted infection are increasing worldwide, with estimates suggesting in excess of 82 million infections each year. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring found that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the American regulatory agency in recent days for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers anticipate that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in close succession. This medication, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a unique collaborative effort for medication research. The non-profit organisation GARDP worked alongside the drug firm its industry partner to develop it.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Data and Global Access

Based on data published in a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which uses an injection and a pill. The trial involved over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to make available and distribute the drug in a wide range of developing nations.

Doctors treating patients have shared positive views. The availability of a one-pill regimen like this is hailed as a "game-changer" for managing the epidemic. This is viewed as crucial to alleviate the strain of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.